Why the study?
Does a prolonged detection interval (NID 30/40) reduce ICD therapies delivered to terminate spontaneous VT in patients with Class I-IIA indication for ICD therapy?
Does a prolonged detection interval (NID 30/40) reduce ICD therapies delivered to terminate spontaneous VT in patients with Class I-IIA indication for ICD therapy?
The ADVANCE III trial is designed to evaluate whether a prolonged detection interval can safely reduce unnecessary ICD therapies for fast ventricular tachyarrhythmias in a general ICD patient cohort.
Answers are grounded in this paper and cite their sources.
Tests whether prolonged detection safely cuts ICD therapies; RCT extends prior data to broad indicated population.
INTRODUCTION: The purpose of this investigation is to evaluate whether a prolonged detection interval for life threatening ventricular tachyarrhythmia (VT) is able to reduce therapies (Rx) delivered by an implantable cardioverter/defibrillator (ICD). Until now, only the PREPARE trial demonstrated a reduction of ICD Rx in a cohort of primary prevention patients. METHODS AND RESULTS: The ADVANCE III study is a prospective, randomized, parallel trial with 2 arms evaluating different intervals to detect (NID), i.e., 18/24 (as currently used) versus 30/40. The primary endpoint is to demonstrate a 20% reduction of ICD Rx (antitachycardia pacing or shocks) delivered to terminate spontaneous VT with a cycle length < or =320 ms in patients with Class I-IIA indication for ICD therapy, regardless of cardiac resynchronization capabilities. The worldwide investigation started in spring 2008 and is expected to be finished in 2011. CONCLUSIONS: The ADVANCE III trial is the first randomized investigation evaluating the reduction of ICD Rx for fast VT due to a prolongation of NID in a general ICD patient cohort.
No takes yet. Share an insight, caveat, or question.
SCHWAB et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: